Findings

What do systematic reviews say?

3 questions · 4 findings · 2 reviews · Lung Cancer

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 2 · 50%High 0 · 0%

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Progression‐free survival · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Progression‐free survival · People with advanced non‐small cell lung cancer

Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).

2 findings from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.19 [0.86, 1.65]
2 studies · 275 participants
Moderate
Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.04 [0.92, 1.17]
2 studies · 1607 participants
Moderate